X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
IkT-148009 (risvodetinib) is a potent, selective small-molecule medication being developed by Inhibikase Therapeutics for the treatment of Parkinson's disease.
Lead Product(s): Risvodetinib
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2024
Details:
Inhibikase product candidate IkT-148009 (risvodetinib), which is a Bcr-abl tyrosine kinase inhibitor. It is being evaluated in the Phase II clinical trial studies for the treatment of Parkinson Disease.
Lead Product(s): Risvodetinib
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
IkT-148009 (risvodetinib succinate) is a oral, potent, selective small-molecule, designed to block the activation of Abl kinase, which is investigated for the treatment of Multiple System Atrophy.
Lead Product(s): Risvodetinib
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2023
Details:
IkT-148009 (risvodetinib) is a oral, potent, selective small-molecule, designed to block the activation of Abl kinase, a clinically validated drug target, to halt and reverse the loss of dopamine-secreting neurons in the brain and GI tract.
Lead Product(s): Risvodetinib
Therapeutic Area: Neurology Product Name: IkT-148009
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
